证券代码：688056 证券简称：莱伯泰科 公告编号：2023-024 北京莱伯泰科仪器股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京莱伯泰科仪器股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日召 开的第四届董事会第七次会议和第四届监事会第七次会议，审议通过了《关于使 用暂时闲置募集资金进行现金管理的议案》，同意公司在保证不影响募集资金投 资项目实施、确保募集资金安全的前提下，使用最高不超过人民币 20,000.00 万 元的暂时闲置募集资金进行现金管理，用于购买投资安全性高、流动性好、发行 主体为有保本承诺的商业银行的保本型理财产品（包括结构性存款、协定存款、 通知存款、定期存款、大额存单等），自公司董事会、监事会审议通过之日起 12 个月内有效。在前述额度及期限范围内，公司可以循环滚动使用。董事会授权董 事长在授权额度和期限内行使投资决策权及签署相关法律文件等，具体事项由公 司财务部负责组织实施。 一、募集资金基本情况 根据中国证券监督管 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2023-020 北京莱伯泰科仪器股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一） 会议召开时间：2023 年 05 月 30 日下午 15:00-16:00 投资者可于 2023 年 05 月 23 日(星期二)至 05 月 29 日(星期一)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zqtzb@labtechgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年年度报告及 2023 年第一季度报告，为便于广大投资者更全 面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计 划于 2023 年 05 月 30 日下午 ...

Financial Performance - In 2022, the company's operating revenue was CNY 355.00 million, a decrease of 3.76% compared to 2021[20]. - The net profit attributable to shareholders was CNY 44.62 million, down 35.71% year-on-year[20]. - The net profit after deducting non-recurring gains and losses was CNY 41.17 million, a decline of 34.64% compared to the previous year[21]. - The gross profit margin for all products was 47.71%, a decrease of 0.73 percentage points year-on-year[23]. - Operating cash flow net amount decreased by 84.53% compared to the previous year, primarily due to increased inventory and related costs[23]. - Basic earnings per share were CNY 0.67, a decline of 35.58% year-on-year, while diluted earnings per share were also CNY 0.67[32]. - The company's total revenue for 2022 was CNY 355 million, a decrease of 3.76% year-on-year[32]. - The main business revenue from experimental analysis instruments and consumables accounted for 91.32% of total revenue, with a decrease of 3.54% compared to 2021[114]. - Operating costs were 185.6356 million RMB, a decrease of 2.40% from the previous year, with a gross margin of 47.71%[114]. Research and Development - The R&D expenditure accounted for 10.82% of operating revenue, an increase of 2.31 percentage points from 2021[22]. - Research and development expenses increased by 22.37% to CNY 38.40 million, representing 10.82% of total revenue[33]. - Total R&D investment increased by 22.37% from the previous year, reaching ¥3,840.17 million, with the ratio of R&D investment to operating income at 10.82%[88]. - The company has established a research and development innovation system for laboratory analytical instruments, accumulating strong technical strength and research results, with core technical personnel publishing multiple SCI articles in domestic and international journals[45]. - The company aims to enhance its R&D capabilities for mid-to-high-end scientific instruments, focusing on automation and intelligent analysis technologies to improve product competitiveness[164]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company has not experienced any situation where more than half of the directors could not guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company has not reported any special arrangements for corporate governance[8]. - The company has received a standard unqualified audit report from its accounting firm[5]. Market and Sales Strategy - The company expanded its laboratory solutions business in the semiconductor and new energy sectors, with about half of the orders coming from new industries[23]. - The company emphasizes brand building and market promotion, focusing on new materials, new energy, and life sciences to enhance brand influence and market penetration[39]. - The company has established a competitive advantage in the R&D, core technology, product quality, and customer resources of experimental analysis instruments, particularly in food testing and environmental monitoring[66]. - The company is actively developing new analytical instruments and sample pretreatment products, aiming to enhance product performance and expand into new fields such as renewable energy and biomedicine[67]. - The company is expanding its market presence in Asia, targeting a 20% market share by the end of 2024[188]. Product Development and Innovation - The company successfully launched the LabMS 5000 ICP-MS/MS for the semiconductor industry, enhancing detection sensitivity and interference resistance[34]. - The ICP-Q-TOF-MS project, aimed at single-cell multi-element detection, is expected to complete project acceptance by the end of 2023[35]. - The company has developed a fully automatic extraction technology that uses organic solvents under high temperature and pressure, improving extraction efficiency and reducing contamination risks[82]. - The company has introduced a fully automatic sample processing system that integrates multiple sample pretreatment technologies, providing comprehensive automation solutions[81]. - The company is committed to developing unique mass spectrometry products and enhancing integration with sample pretreatment systems for life sciences research[166]. Financial Management - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares, totaling 13,447,280.00 RMB, which represents 30.13% of the net profit attributable to shareholders for 2022[5]. - The net cash flow from operating activities was CNY 7.5940 million, a significant decline of 84.53% compared to the previous year[114]. - The net cash flow from investing activities was CNY -117.53 million, compared to CNY 19.54 million in the previous year, indicating a decrease in investment income[117]. - The net cash flow from financing activities was CNY -22.82 million, with dividend distribution increasing to CNY 23.52 million from CNY 20.10 million in the previous year[118]. - The company’s procurement strategy includes centralized planning and long-term pricing, aligning well with its sales and production models to support future growth[61]. Human Resources - The number of R&D personnel increased to 120, accounting for 23.81% of the total workforce, up from 22.70% in the previous year[96]. - The average salary of R&D personnel rose to 21.16 million RMB, compared to 19.76 million RMB in the previous year[96]. - The company experienced a notable increase in employee compensation, rising by 9.49% during the reporting period[116]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period was 7.2831 million RMB[196]. - The company continues to focus on the remuneration of its core technical personnel, reflecting its commitment to retaining key talent[196]. Strategic Initiatives - The company plans to hold the 2022 first temporary shareholders' meeting as proposed in the board meeting[200]. - The company is set to implement the 2022 restricted stock incentive plan and related management measures[200]. - The company is considering changes to its registered capital and amendments to its articles of association[200]. - The company will continue to focus on internal control and audit reports to ensure compliance and operational efficiency[198]. - The company aims to achieve continuous revenue growth by increasing brand recognition and market share through diverse product offerings and efficient after-sales service[164].

2023 年第一季度报告 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 | | --- | --- | --- | | | | 同期增减变动幅 | | | | 度(%) | | 营业收入 | 96,598,763.37 | 24.68 | | 归属于上市公司股东的净利润 | 12,867,741.35 | 7.99 | | 归属于上市公司股东的扣除非 | 11,828,050.82 | 5.89 | ...

编号：2022-004 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|----------------------------------------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | 现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 会议时间、参与 | 2022 年 4 月 6 日上午 | 现场调研 | | 单位名称及会 | 中欧基金 | | | 议方式 | 2022 年 4 月 26 日上午 | 电话会议 | | | | 景从资产，国金证券，天贝合资产，华泰证券，神农投资， TANYI | | | Consulting | ，华西证券，东方证券，勤远投资，东方资本，信达证券，上 | | | 2022 年 ...

证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |-----------------------|----------------------------------|-----------------------------------------------------------------------| | | | | | 投资者关系 | □特定对象调研 □分析师会议 | | | 活动类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名 | 2022 年 5 月 19 日下午 | | | 称 | 广大投资者 | | | | | | | 会议时间及 会议方式 | 2022 年 5 月 19 日下午 | 通过上证路演中心视频录播、网络文字互动相结合的方式 | | 上市公司接 | 董事长兼总经理，胡克 | | | 待人员姓名 | 董事、董事会秘书兼财务总监，于浩 | | | ...

编号：2022-007 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------------|----------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | 现场参观 | | | | 其他 | （请文字说明其他活动内容）策略会 | | | | | | 会议时间、参与 | 2022 年 6 月 1 日下午 | 电话会议 | | 单位名称及会 | 华创证券，农银汇理基金 | | | 议方式 | 2022 年 6 月 2 日下午 | 电话会议 | | | 民生证券，广发基金 | | | | 2022 年 6 月 6 日下午 | 电话会议 | | | 民生证券，华商基金 | | | | 2022 年 6 月 6 日下午 | 电话会议 | | | 华创证券，万家基金 | | ...

编号：2022-006 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------------|----------------------------------------------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 | （请文字说明其他活动内容）策略会 | | 会议时间、参与 | 2022 年 5 月 9 日下午 | 策略会 | | 单位名称及会 | | 华创证券，华创证券自营，进门财经，高信百诺，华商基金，新华基金， | | 议方式 | | 歌斐资产，金百镕投资，浦银安盛基金，中银国际证券，安信基金，熙 | | | 2022 年 5 月 13 日下午 东方证券， ...

2022 年第三季度报告 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | 单位：元 币种：人民币 | | --- | | 项目 | 本报告期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损 | | -2,847.11 | | | 益 | | | | | 越权审批，或无正式 | | | | | 批准文件，或偶发性 | | | | | 的税收返还、减免 | | | | | 计入当期损益的政府 | 6 ...

Financial Performance - The company reported a total revenue of RMB 300 million for the first half of 2022, representing a year-on-year increase of 15%[12]. - The company's operating revenue for the first half of 2022 was CNY 155,516,645.45, a decrease of 14.62% compared to the same period last year[18]. - The net profit attributable to shareholders was CNY 22,097,910.67, down 35.18% year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 20,440,370.72, a decline of 38.40% compared to the previous year[18]. - The gross profit margin improved to 45%, up from 40% in the same period last year, reflecting better cost management[12]. - The company reported a total revenue of 6,900 million RMB, with a year-on-year increase of 1,173.76 million RMB, representing a growth of approximately 20.5%[50]. - The company's operating revenue for the reporting period was ¥155,516,645.45, a decrease of 14.62% compared to ¥182,153,328.85 in the same period last year[72]. - Net profit attributable to shareholders was 22.10 million yuan, down 35.18% year-on-year, with a non-recurring net profit of 20.44 million yuan, down 38.40%[56]. Research and Development - Research and development expenses increased by 25% to RMB 50 million, focusing on new technologies in analytical instruments[12]. - The R&D expenditure accounted for 10.98% of operating revenue, an increase of 3.24 percentage points year-on-year[19]. - The company achieved a total R&D investment of ¥17,079,801.28, representing a 21.08% increase compared to the previous year[41]. - R&D investment accounted for 10.98% of total revenue, up from 7.74% in the same period last year, indicating a 3.24 percentage point increase[41]. - The company has obtained a total of 96 authorized patents, including 2 new invention patents during the reporting period[38]. - The company has developed a fully automated experimental detection platform that integrates sample collection, processing, automated injection, analysis, and intelligent data analysis[25]. - The company is developing a fully automatic sample purification instrument for radioactive element extraction, which replaces manual operations to avoid radiation exposure[36]. Market Expansion and Strategy - The company expects a revenue growth forecast of 10% for the second half of 2022, driven by new product launches and market expansion strategies[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[12]. - The company is focusing on expanding its product offerings and enhancing the performance of its existing products to meet the growing demands of downstream application fields[34]. - The company is actively developing new sample pretreatment products and analysis testing instruments to enhance product performance and expand its market share in food testing and environmental monitoring[34]. - The company is focusing on expanding its market presence in the life sciences, food, and environmental sectors, with significant applications in disease control[45]. Shareholder and Governance Matters - The board has approved a share buyback program of up to RMB 20 million to enhance shareholder value[12]. - The company has committed to maintaining a dividend payout ratio of K%, ensuring consistent returns for investors[117]. - The company will strictly adhere to the relevant laws and regulations regarding shareholding lock-up commitments and will not engage in any share reduction behavior that violates these commitments during the lock-up period[118]. - The company has established a commitment to adhere to the rules regarding share transfer for directors and senior management[106]. - The company will ensure that any share reduction price will not be lower than the IPO price within 2 years post-lock-up[106]. Operational Challenges - The decline in revenue and profit was primarily attributed to the impact of COVID-19 on operations, particularly in East and North China[18]. - The company increased its inventory by CNY 24,123,000 due to longer procurement cycles and anticipated price increases for raw materials[18]. - The project for upgrading the intelligent analysis detection system production line faced delays due to local pandemic control measures, affecting construction progress[152]. - The project for the production of experimental analysis instrument consumables was impacted by global pandemic-related shipping and personnel restrictions, causing delays in equipment arrival and training[153]. Corporate Social Responsibility - The company has implemented environmental protection measures, including the recovery and treatment of industrial wastewater and solid waste, ensuring compliance with pollution discharge standards[98]. - In July 2022, the company donated to the Tianjin Red Cross to support rural revitalization efforts in Gansu Province[100]. - The company signed a partnership agreement in August 2022 to assist in economic development and improve working conditions in a village in Inner Mongolia[100].